LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Diacerein

    de Oliveira, Pedro Gonçalves / Termini, Lara / Durigon, Edison Luiz / Lepique, Ana Paula / Sposito, Andrei C / Boccardo, Enrique

    Medical Hypotheses

    A potential multi-target therapeutic drug for COVID-19

    2020  Volume 144, Page(s) 109920

    Keywords General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109920
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1132: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Diacerein: A potential multi-target therapeutic drug for COVID-19.

    de Oliveira, Pedro Gonçalves / Termini, Lara / Durigon, Edison Luiz / Lepique, Ana Paula / Sposito, Andrei C / Boccardo, Enrique

    Medical hypotheses

    2020  Volume 144, Page(s) 109920

    Abstract: ... that DAR is a multi-target drug useful for COVID-19 treatment. This anthraquinone may control ... The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 ... COVID-19), was declared pandemic by the World Health Organization in March 2020. SARS-CoV-2 binds ...

    Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 19 (COVID-19), was declared pandemic by the World Health Organization in March 2020. SARS-CoV-2 binds its host cell receptor, angiotensin-converting enzyme 2 (ACE2), through the viral spike (S) protein. The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients has been suggested to be connected with cytokine storm syndrome (CSS), an excessive immune response that severely damages healthy lung tissue. In addition, cardiac symptoms, including fulminant myocarditis, are frequent in patients in a severe state of illness. Diacerein (DAR) is an anthraquinone derivative drug whose active metabolite is rhein. Different studies have shown that this compound inhibits the IL-1, IL-2, IL-6, IL-8, IL-12, IL-18, TNF-α, NF-κB and NALP3 inflammasome pathways. The antiviral activity of rhein has also been documented. This metabolite prevents hepatitis B virus (HBV) replication and influenza A virus (IAV) adsorption and replication through mechanisms involving regulation of oxidative stress and alterations of the TLR4, Akt, MAPK, and NF-κB signalling pathways. Importantly, rhein inhibits the interaction between the SARS-CoV S protein and ACE2 in a dose-dependent manner, suggesting rhein as a potential therapeutic agent for the treatment of SARS-CoV infection. Based on these findings, we hypothesize that DAR is a multi-target drug useful for COVID-19 treatment. This anthraquinone may control hyperinflammatory conditions by multi-faceted cytokine inhibition and by reducing viral infection.
    MeSH term(s) Angiotensin-Converting Enzyme 2/drug effects ; Angiotensin-Converting Enzyme 2/metabolism ; Animals ; Anthraquinones/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Antiviral Agents/therapeutic use ; COVID-19/metabolism ; COVID-19/virology ; Cytokines/metabolism ; Drug Evaluation, Preclinical ; Host Microbial Interactions/drug effects ; Humans ; Male ; Mice, Inbred C57BL ; Models, Biological ; Oxidation-Reduction/drug effects ; Pandemics ; Receptors, Coronavirus/drug effects ; Receptors, Coronavirus/metabolism ; SARS-CoV-2/drug effects ; Signal Transduction/drug effects ; Virus Replication/drug effects ; COVID-19 Drug Treatment
    Chemical Substances Anthraquinones ; Anti-Inflammatory Agents ; Antiviral Agents ; Cytokines ; Receptors, Coronavirus ; diacerein (4HU6J11EL5) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Keywords covid19
    Language English
    Publishing date 2020-06-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109920
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1132: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Diacerein: A potential multi-target therapeutic drug for COVID-19

    de Oliveira, Pedro Gonçalves / Termini, Lara / Durigon, Edison Luiz / Lepique, Ana Paula / Sposito, Andrei C / Boccardo, Enrique

    Med Hypotheses

    Abstract: ... we hypothesize that DAR is a multi-target drug useful for COVID-19 treatment. This anthraquinone may control ... The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 ... COVID-19), was declared pandemic by the World Health Organization in March 2020. SARS-CoV-2 binds ...

    Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 19 (COVID-19), was declared pandemic by the World Health Organization in March 2020. SARS-CoV-2 binds its host cell receptor, angiotensin-converting enzyme 2 (ACE2), through the viral spike (S) protein. The mortality related to severe acute respiratory distress syndrome (ARDS) and multi-organ failure in COVID-19 patients has been suggested to be connected with cytokine storm syndrome (CSS), an excessive immune response that severely damages healthy lung tissue. In addition, cardiac symptoms, including fulminant myocarditis, are frequent in patients in a severe state of illness. Diacerein (DAR) is an anthraquinone derivative drug whose active metabolite is rhein. Different studies have shown that this compound inhibits the IL-1, IL-2, IL-6, IL-8, IL-12, IL-18, TNF-α, NF-κB and NALP3 inflammasome pathways. The antiviral activity of rhein has also been documented. This metabolite prevents hepatitis B virus (HBV) replication and influenza A virus (IAV) adsorption and replication through mechanisms involving regulation of oxidative stress and alterations of the TLR4, Akt, MAPK, and NF-κB signalling pathways. Importantly, rhein inhibits the interaction between the SARS-CoV S protein and ACE2 in a dose-dependent manner, suggesting rhein as a potential therapeutic agent for the treatment of SARS-CoV infection. Based on these findings, we hypothesize that DAR is a multi-target drug useful for COVID-19 treatment. This anthraquinone may control hyperinflammatory conditions by multi-faceted cytokine inhibition and by reducing viral infection.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #457482
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top